Valneva SE

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

20 Jun 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Settlement Agreement with the UK Government

15 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

10 Jun 2022 12:30:00 By Nasdaq GlobeNewswire

Valneva Joins Euronext’s Tech Leaders Index

08 Jun 2022 02:30:00 By Nasdaq GlobeNewswire

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

07 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

03 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Shareholder Meetings

02 Jun 2022 14:50:00 By Nasdaq GlobeNewswire

Valneva Appoints Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board

31 May 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

25 May 2022 01:00:00 By Nasdaq GlobeNewswire

EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

19 May 2022 01:00:00 By Nasdaq GlobeNewswire